HRP20131014T1 - Kompozicija i postupci poveä†anja mineralizacije kostiju - Google Patents
Kompozicija i postupci poveä†anja mineralizacije kostiju Download PDFInfo
- Publication number
- HRP20131014T1 HRP20131014T1 HRP20131014TT HRP20131014T HRP20131014T1 HR P20131014 T1 HRP20131014 T1 HR P20131014T1 HR P20131014T T HRP20131014T T HR P20131014TT HR P20131014 T HRP20131014 T HR P20131014T HR P20131014 T1 HRP20131014 T1 HR P20131014T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- fragment
- binds
- antigen
- seq
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 230000018678 bone mineralization Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 208000029725 Metabolic bone disease Diseases 0.000 claims 3
- 206010049088 Osteopenia Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 201000000304 Cleidocranial dysplasia Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000000088 Enchondromatosis Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000035175 Oligomenorrhea Diseases 0.000 claims 1
- 206010030295 Oligomenorrhoea Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 208000002607 Pseudarthrosis Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 102000019307 Sclerostin Human genes 0.000 claims 1
- 108050006698 Sclerostin Proteins 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010047623 Vitamin C deficiency Diseases 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010103 fibrous dysplasia Diseases 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 206010031281 osteopoikilosis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000010233 scurvy Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
Claims (15)
1. Antitijelo ili njegov fragment koji se veže na antigen, koje se veže specifično na sklerostin polipeptid koji sadrži aminokiselinski slijed prikazan u SEQ ID NO: 46, naznačen time da se antitijelo ili njegov fragment veže na slijed SEQ ID NO: 98.
2. Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, naznačen time da se antitijelo ili njegov fragment veže na slijed SEQ ID NO: 74.
3. Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, naznačen time da se antitijelo ili njegov fragment veže na slijed SEQ ID NO: 75.
4. Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, naznačen time da se specifično veže na najmanje četiri uzastopne aminokiseline iz SEQ ID NO : 46.
5. Antitijelo ili njegov fragment koji se veže na antigen prema bilo kojem od prethodnih zahtjeva, naznačen time da je antitijelo poliklonsko ili monoklonsko.
6. Antitijelo ili njegov fragment koji se veže na antigen prema bilo kojem od prethodnih zahtjeva, naznačen time da je antitijelo ljudsko, humanizirano ili himerno.
7. Fragment koji se veže na antigen prema bilo kojem od prethodnih zahtjeva, naznačen time da je odabran između F(ab')2, Fab, Fab', Fd i FV.
8. Stanica domaćin naznačena time da proizvodi ili izražava antitijelo ili fragment prema bilo kojem od prethodnih zahtjeva.
9. Stanica domaćin u skladu s patentnim zahtjevom 8, naznačena time da je to hibridoma stanica.
10. Polinukleotid naznačen time da kodira antitijela ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 7.
11. Uporaba stanice domaćina u skladu s patentnim zahtjevom 8 ili 9, naznačena time da je namijenjena proizvodnji ili izražavanju navedenog protutijela ili fragmenta.
12. Pripravak prema bilo kojem od zahtjeva 1 do 7, naznačen time da sadrži antitijelo ili njegov fragment koji se veže na antigen, i fiziološki prihvatljiv nosač.
13. Antitijelo ili njegov fragment koji se veže na antigen prema bilo kojem od zahtjeva 1 do 7, naznačen time da je namijenjen uporabi u postupku povećanja mineralnog sadržaja kostiju i/ili mineralne gustoće kosti u toplokrvne životinje ili čovjeka.
14. Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 13, naznačen time da se koristi za u liječenju osteopenije, osteoporoze, prijeloma, ahondroplazije, kleidrokranialne dizostose, enhondromatoze, fibrozne displazije, Gaucher-ove bolesti, hipofosfatemičnog rahitisa, Marfanova sindroma, multiple nasljedne egzotoze, neurofibromatoze, osteogeneze imperfekte, osteoporoze, osteopoikiloze, sklerotičnih lezija, parodontalnih bolesti, pseudoartroze ili piogeničnog osteomijelitisa.
15. Antitijelo ili njegov fragment koji se veže na antigen za upotrebu prema zahtjevu 14, naznačen time da je osteopenija uzrokovana anemičnim stanjem, steroidima, heparinom, poremećajem koštane srži, skorbutom, pothranjenošću, nedostatkom kalcija, idiopatskom osteoporozom, prirođenom osteopenijom ili osteoporozom, alkoholizmom, kroničnom bolešću jetre, senilnošću, postmenopauzom, oligomenoreom, amenoreom, trudnoćom, dijabetesom, hipertireozom, Cushingovm bolešću, akromegalijom, hipogonadizmom, imobilizacijom ili neupotrebom, sindromom refleksne simpatičke distrofije, prelaznom regionalnom osteoporozom ili osteomalacijom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/463,190 US20040009535A1 (en) | 1998-11-27 | 2003-06-16 | Compositions and methods for increasing bone mineralization |
| PCT/US2004/018910 WO2005003158A2 (en) | 2003-06-16 | 2004-06-15 | Compositions and methods for increasing bone mineralization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131014T1 true HRP20131014T1 (hr) | 2013-12-20 |
Family
ID=33563705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131014TT HRP20131014T1 (hr) | 2003-06-16 | 2013-10-24 | Kompozicija i postupci poveä†anja mineralizacije kostiju |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20040009535A1 (hr) |
| EP (3) | EP1638999B1 (hr) |
| JP (2) | JP4818107B2 (hr) |
| KR (1) | KR101221147B1 (hr) |
| CN (2) | CN1835968B (hr) |
| AU (1) | AU2004253870B2 (hr) |
| BR (1) | BRPI0411535A (hr) |
| CA (1) | CA2529578C (hr) |
| CY (1) | CY1114701T1 (hr) |
| DK (1) | DK1638999T3 (hr) |
| EA (2) | EA014525B1 (hr) |
| ES (1) | ES2428767T3 (hr) |
| HK (1) | HK1088907A1 (hr) |
| HR (1) | HRP20131014T1 (hr) |
| IL (2) | IL172599A (hr) |
| ME (2) | ME00023B (hr) |
| NO (1) | NO20060235L (hr) |
| NZ (1) | NZ544617A (hr) |
| PL (1) | PL1638999T3 (hr) |
| PT (1) | PT1638999E (hr) |
| RS (1) | RS52769B (hr) |
| SG (1) | SG185824A1 (hr) |
| SI (1) | SI1638999T1 (hr) |
| WO (1) | WO2005003158A2 (hr) |
| ZA (1) | ZA200600384B (hr) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| NZ512122A (en) | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| EP1575481A4 (en) * | 2002-03-01 | 2010-01-06 | Celltech R & D Inc | PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US20100041599A1 (en) * | 2006-11-14 | 2010-02-18 | Dakai Liu | Compositions and methods for bone formation, bone remodeling and toxin protection |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| WO2005115439A2 (en) | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| ES2426005T3 (es) | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
| ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US7901710B2 (en) * | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263137B2 (en) * | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US7998500B2 (en) * | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8202546B2 (en) * | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CN105001320A (zh) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| WO2007124486A2 (en) * | 2006-04-21 | 2007-11-01 | Childrens Hospital Los Angeles | Bmp4 inhibitors |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| US20100036091A1 (en) * | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| AU2007332819A1 (en) | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| SI3345607T1 (sl) | 2006-12-29 | 2023-03-31 | Ossifi-Mab Llc | Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| ME02333B (me) | 2007-02-09 | 2013-04-30 | Acceleron Pharma Inc | FARMACEUTSKE SMEŠE KOJE SADRŽE AKTIVIN-ActRIIA ANTAGONISTE I NJIHOVA UPOTREBA U PREVENCIJI ILI LEČENJU MULTIPLOG MIJELOMA |
| CN101646457B (zh) | 2007-03-20 | 2013-05-01 | 伊莱利利公司 | 抗硬骨素抗体 |
| US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
| US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8608049B2 (en) | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
| WO2009110215A1 (ja) * | 2008-03-03 | 2009-09-11 | 独立行政法人 科学技術振興機構 | 繊毛細胞の分化誘導方法 |
| WO2010002835A2 (en) * | 2008-07-03 | 2010-01-07 | Osteogenex, Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth |
| TWI748373B (zh) | 2008-08-14 | 2021-12-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | METHODS FOR INCREASING ADIPONECTIN |
| ES2545614T3 (es) * | 2009-02-06 | 2015-09-14 | Pepscan Systems Bv | Proteínas truncadas con nudo de cistina |
| US8338377B2 (en) * | 2009-03-30 | 2012-12-25 | Acceleron Pharma Inc. | BMP-ALK3 antagonists and uses for promoting bone growth |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| EP3805259A1 (en) | 2009-06-12 | 2021-04-14 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US20130138221A1 (en) | 2010-04-16 | 2013-05-30 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| SG185465A1 (en) | 2010-05-14 | 2012-12-28 | Amgen Inc | High concentration antibody formulations |
| US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
| US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
| US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
| US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
| KR20180019247A (ko) | 2010-11-05 | 2018-02-23 | 노파르티스 아게 | Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법 |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| EA201391248A1 (ru) | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
| CR20160147A (es) | 2011-03-25 | 2016-08-03 | Amgen Inc | Formulaciones de anticuerpos |
| FR2974061B1 (fr) | 2011-04-13 | 2013-06-07 | Michelin Soc Tech | Procede et dispositif de comptage du nombre d'atterrissages d'un pneumatique d'un aeronef |
| DK2699261T3 (en) | 2011-04-19 | 2018-09-17 | Amgen Inc | Method of treating osteoporosis |
| US20140056912A1 (en) | 2011-04-29 | 2014-02-27 | Novartis Ag | Methods of treating squamous cell carcinoma |
| US8895254B2 (en) * | 2011-07-19 | 2014-11-25 | University Health Network | Biomarkers for ankylosing spondylitis |
| EP2739311B9 (en) | 2011-08-04 | 2018-09-19 | Amgen Inc. | Method for treating bone gap defects |
| EP3453711B1 (en) | 2011-09-02 | 2021-08-18 | The Regents of the University of California | Llp2a- bisphosphonate conjugates for osteoporosis treatment |
| KR20200056473A (ko) | 2011-12-28 | 2020-05-22 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| CA2890217C (en) | 2012-11-02 | 2021-07-20 | Yifu FANG | Activin-actrii antagonists and uses for treating bone and other disorders |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| LT2976359T (lt) * | 2013-03-20 | 2018-12-27 | Genzyme Corporation | Nebaigtinės osteogenezės gydymo būdai |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3154566B1 (en) | 2014-06-13 | 2022-08-03 | Acceleron Pharma Inc. | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP4233889A3 (en) | 2014-12-03 | 2023-10-11 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| JP2019527710A (ja) | 2016-08-08 | 2019-10-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた結合組織付着の改善方法 |
| GB201621907D0 (en) * | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| CN110325548B (zh) | 2016-12-21 | 2023-11-17 | 美莱奥生物制药第三有限公司 | 抗硬化蛋白抗体在治疗成骨不全症中的用途 |
| RU2651091C1 (ru) * | 2016-12-22 | 2018-04-18 | Федеральное Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) | Способ диагностики остеомиелита у детей |
| US20210198672A1 (en) * | 2018-02-12 | 2021-07-01 | Aptacure Therapeutics Limited | Aptamer for sclerostin and use thereof |
| CA3093457A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| US20210308265A1 (en) | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
| MX2022001805A (es) | 2019-08-12 | 2022-06-08 | Amgen Inc | Formulaciones de anticuerpos anti-esclerostina. |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US751929A (en) | 1904-02-09 | Ash-pan | ||
| US793398A (en) | 1905-03-24 | 1905-06-27 | Herschel A Schermerhorn | Fastening for wagon eng-gates. |
| US4018884A (en) | 1975-06-26 | 1977-04-19 | Hoffmann-La Roche Inc. | Fluorogenic materials and labeling techniques |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4528266A (en) | 1979-10-01 | 1985-07-09 | George Pieczenik | Method of inserting unique DNA sequences into DNA vectors |
| US4359535A (en) | 1979-10-01 | 1982-11-16 | George Pieczenik | Autonomously replicating DNA containing inserted DNA sequences |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5087571A (en) | 1984-06-22 | 1992-02-11 | President And Fellows Of Harvard College | Method for providing a cell culture from a transgenic non-human mammal |
| JP2624470B2 (ja) | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
| US5272254A (en) | 1984-10-02 | 1993-12-21 | Biogen Inc. | Production of streptavidin-like polypeptides |
| US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| SG64329A1 (en) | 1984-11-16 | 1999-04-27 | American Cyanamid Co | Antitumor antibiotics (LL-E33288 complex) |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
| US4744981A (en) | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE132266T1 (de) | 1987-05-01 | 1996-01-15 | Stratagene Inc | Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8723661D0 (en) | 1987-10-08 | 1987-11-11 | British Bio Technology | Synthetic gene |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| DE3851682T2 (de) | 1987-10-30 | 1995-05-04 | American Cyanamid Co | Targetformer von Antitumor-Methyltrithioagenzien. |
| US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
| EP0329184A3 (en) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
| US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| GB8903022D0 (en) | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
| US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| AU5741590A (en) | 1989-05-04 | 1990-11-29 | Southern Research Institute | Improved encapsulation process and products therefrom |
| GB8914543D0 (en) | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| KR920007887B1 (ko) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | 내연기관의 배기가스 정화장치 |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5359051A (en) | 1990-01-11 | 1994-10-25 | Isis Pharmaceuticals | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| WO1991019810A1 (en) | 1990-06-15 | 1991-12-26 | California Biotechnology Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| AU662304B2 (en) | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
| US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| DE4135543A1 (de) | 1991-10-28 | 1993-04-29 | Boehringer Mannheim Gmbh | Rekombinantes core-streptavidin |
| US5203975A (en) | 1991-10-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Process for cathodic electrodeposition of a clear coating over a conductive paint layer |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5910573A (en) | 1992-01-23 | 1999-06-08 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Monomeric and dimeric antibody-fragment fusion proteins |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0578515A3 (en) | 1992-05-26 | 1995-05-10 | Bristol Myers Squibb Co | Humanized monoclonal antibodies. |
| WO1993024631A1 (en) | 1992-05-29 | 1993-12-09 | E.I. Du Pont De Nemours And Company | PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS) |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5928647A (en) | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
| IL108719A0 (en) | 1993-02-25 | 1994-08-26 | Ortho Pharma Corp | Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them |
| FR2702160B1 (fr) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
| FR2704145B1 (fr) | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| AU700371B2 (en) | 1993-06-07 | 1999-01-07 | Genentech Inc. | Hiv envelope polypeptides |
| JPH09506857A (ja) | 1993-07-16 | 1997-07-08 | オントーゲン コーポレーション | 多成分組合せアレイ合成による有機化合物の組合せアレイの合成 |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| WO1995004277A1 (en) | 1993-08-03 | 1995-02-09 | Sphinx Pharmaceuticals Corporation | A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
| AU1068295A (en) | 1993-12-09 | 1995-06-27 | Novartis Ag | Process for the production of combinatorial compound libraries |
| AU7552394A (en) | 1993-12-15 | 1995-07-03 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| JPH09506913A (ja) | 1993-12-15 | 1997-07-08 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| WO1995024186A1 (en) | 1994-03-11 | 1995-09-14 | Pharmacopeia, Inc. | Sulfonamide derivatives and their use |
| US5863738A (en) | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
| AU691296B2 (en) | 1994-05-06 | 1998-05-14 | Pharmacopeia Drug Discovery, Inc. | Combinatorial dihydrobenzopyran library |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5792456A (en) | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| KR20000015893A (ko) | 1996-05-22 | 2000-03-15 | 댄 마이클 | 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도 |
| US6958239B2 (en) | 1996-11-21 | 2005-10-25 | Oligos Etc Inc. | Three component chimeric antisense oligonucleotides |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| EP1367124A1 (en) | 1997-08-01 | 2003-12-03 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| ID26669A (id) | 1998-02-12 | 2001-01-25 | Immune Complex Corp | Inti protein-protein hepatitis b yang dimodifikasi secara strategi dan turunan-turunannya |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| NZ512122A (en) * | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| ATE444971T1 (de) | 1999-06-09 | 2009-10-15 | Genentech Inc | Zusammensetzungen und verfahren für die tumor- behandlung |
| JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
| JP2003525611A (ja) | 2000-03-02 | 2003-09-02 | アムジェン インコーポレーテッド | コルディン様−２分子およびその使用 |
| WO2001092308A2 (en) * | 2000-06-01 | 2001-12-06 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| EP1366156A2 (en) | 2000-06-19 | 2003-12-03 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| JP4451059B2 (ja) | 2000-09-01 | 2010-04-14 | ジェネンテック インコーポレイテッド | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| CA2529623A1 (en) * | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CN101646457B (zh) * | 2007-03-20 | 2013-05-01 | 伊莱利利公司 | 抗硬骨素抗体 |
| AR068767A1 (es) * | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
-
2003
- 2003-06-16 US US10/463,190 patent/US20040009535A1/en not_active Abandoned
-
2004
- 2004-06-15 SG SG2008068264A patent/SG185824A1/en unknown
- 2004-06-15 CA CA2529578A patent/CA2529578C/en not_active Expired - Lifetime
- 2004-06-15 ME MEP-2008-31A patent/ME00023B/me unknown
- 2004-06-15 CN CN2004800233260A patent/CN1835968B/zh not_active Expired - Lifetime
- 2004-06-15 EP EP04776552.4A patent/EP1638999B1/en not_active Expired - Lifetime
- 2004-06-15 EA EA200600037A patent/EA014525B1/ru not_active IP Right Cessation
- 2004-06-15 RS YU20050932A patent/RS52769B/sr unknown
- 2004-06-15 EP EP10013087A patent/EP2338906A1/en not_active Ceased
- 2004-06-15 BR BRPI0411535-0A patent/BRPI0411535A/pt not_active Application Discontinuation
- 2004-06-15 KR KR1020057024173A patent/KR101221147B1/ko active IP Right Grant
- 2004-06-15 EA EA201001528A patent/EA022991B1/ru not_active IP Right Cessation
- 2004-06-15 ME MEP-31/08A patent/MEP3108A/xx unknown
- 2004-06-15 EP EP10013086A patent/EP2341071A1/en not_active Withdrawn
- 2004-06-15 AU AU2004253870A patent/AU2004253870B2/en active Active
- 2004-06-15 JP JP2006517259A patent/JP4818107B2/ja not_active Expired - Lifetime
- 2004-06-15 DK DK04776552.4T patent/DK1638999T3/da active
- 2004-06-15 NZ NZ544617A patent/NZ544617A/en not_active IP Right Cessation
- 2004-06-15 CN CN2012105588665A patent/CN103319596A/zh active Pending
- 2004-06-15 ES ES04776552T patent/ES2428767T3/es not_active Expired - Lifetime
- 2004-06-15 WO PCT/US2004/018910 patent/WO2005003158A2/en active Application Filing
- 2004-06-15 PL PL04776552T patent/PL1638999T3/pl unknown
- 2004-06-15 SI SI200432101T patent/SI1638999T1/sl unknown
- 2004-06-15 PT PT47765524T patent/PT1638999E/pt unknown
-
2005
- 2005-01-16 NO NO20060235A patent/NO20060235L/no not_active Application Discontinuation
- 2005-12-15 IL IL172599A patent/IL172599A/en active IP Right Grant
-
2006
- 2006-01-13 ZA ZA200600384A patent/ZA200600384B/xx unknown
- 2006-04-05 US US11/399,210 patent/US7578999B2/en not_active Expired - Lifetime
- 2006-08-16 HK HK06109124.4A patent/HK1088907A1/xx not_active IP Right Cessation
-
2009
- 2009-07-16 US US12/504,296 patent/US7985834B2/en not_active Expired - Lifetime
-
2011
- 2011-07-19 JP JP2011157675A patent/JP2011246482A/ja active Pending
-
2012
- 2012-10-29 IL IL222756A patent/IL222756A0/en unknown
-
2013
- 2013-10-09 CY CY20131100883T patent/CY1114701T1/el unknown
- 2013-10-24 HR HRP20131014TT patent/HRP20131014T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131014T1 (hr) | Kompozicija i postupci poveä†anja mineralizacije kostiju | |
| HRP20170514T1 (hr) | Epitopi sklerostina | |
| US20240209075A1 (en) | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization | |
| HRP20150597T1 (hr) | Sredstva ta vezivanje sklerostina | |
| HRP20160872T1 (hr) | Postupak za inhibiciju resorpcije kosti | |
| HRP20201085T1 (hr) | Humanizirana, mišja ili himerna anti-cd47 monoklonalna antitijela | |
| US20190153086A1 (en) | Heterodimeric Immunoglobulins | |
| JP2019508030A5 (hr) | ||
| RU2017134592A (ru) | Антитела к muc16 и их применение | |
| HRP20201266T1 (hr) | Anti fg23 antitijelo i farmaceutski pripravak koji sadrži isto | |
| RU2010116256A (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2013535970A5 (hr) | ||
| JP2018203735A5 (hr) | ||
| RU2021129725A (ru) | Фармацевтическая композиция, содержащая антитело против il-5, и ее применение | |
| RU2021136291A (ru) | Антитело против фактора роста соединительной ткани и его применение | |
| SG182001A1 (en) | Antibodies specific for sclerostin and methods for increasing bone mineralization |